Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on December 22, 2011. The report discloses a private placement of common stock that closed on December 28, 2011.
Key Financial Metrics
- Shares Issued: 1,809,653 shares of common stock.
- Price Per Share: $1.15.
- Gross Proceeds: $2,081,101.
- Placement Agent Commissions: $145,677 paid to Rodman & Renshaw, LLC.
- Net Proceeds: Approximately $1,935,424 (calculated as gross proceeds minus commissions).
- Warrant Coverage: None.
Material Changes
The filing reports a material capital event: the execution of agreements with institutional and accredited investors to raise capital. This transaction increased the company's equity base and cash liquidity. The offering was conducted pursuant to a shelf registration statement (File No. 333-171411) declared effective on May 3, 2011.
Guidance, Outlook, and Risks
Use of Proceeds: Management anticipates using net proceeds for general corporate purposes and to fund several important growth opportunities.
Forward-Looking Statements: The filing contains forward-looking statements regarding intentions, beliefs, and strategies. Management notes these are based on current assumptions and are not guarantees of future performance. Actual results may differ materially due to risks discussed in the company's Annual Report on Form 10-K.
Legal Disclaimer: The report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful without registration.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-issuance to assess dilution impact.
- Confirm the specific "growth opportunities" referenced in the use of proceeds section.
- Review the company's most recent Form 10-K for detailed risk factors mentioned in the forward-looking statement disclaimer.
- Check subsequent filings to confirm the final closing date and any additional terms not detailed in this summary.